false2021Q200008597379-28P6MP1YP1YP1YP1Y00008597372020-09-272021-03-27xbrli:shares00008597372021-04-22iso4217:USD00008597372020-12-272021-03-2700008597372019-12-292020-03-2800008597372019-09-292020-03-28iso4217:USDxbrli:shares00008597372021-03-2700008597372020-09-260000859737us-gaap:CommonStockMember2019-09-280000859737us-gaap:AdditionalPaidInCapitalMember2019-09-280000859737us-gaap:RetainedEarningsMember2019-09-280000859737us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-09-280000859737us-gaap:TreasuryStockMember2019-09-2800008597372019-09-2800008597372019-09-292019-12-280000859737us-gaap:RetainedEarningsMemberus-gaap:AccountingStandardsUpdate201801Member2019-09-280000859737us-gaap:CommonStockMember2019-09-292019-12-280000859737us-gaap:AdditionalPaidInCapitalMember2019-09-292019-12-280000859737us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-09-292019-12-280000859737us-gaap:TreasuryStockMember2019-09-292019-12-280000859737holx:ShareRepurchaseProgramMemberus-gaap:TreasuryStockMember2019-09-292019-12-280000859737us-gaap:CommonStockMember2019-12-280000859737us-gaap:AdditionalPaidInCapitalMember2019-12-280000859737us-gaap:RetainedEarningsMember2019-12-280000859737us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-280000859737us-gaap:TreasuryStockMember2019-12-2800008597372019-12-280000859737us-gaap:CommonStockMember2019-12-292020-03-280000859737us-gaap:AdditionalPaidInCapitalMember2019-12-292020-03-280000859737us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-292020-03-280000859737us-gaap:TreasuryStockMember2019-12-292020-03-280000859737holx:ShareRepurchaseProgramMemberus-gaap:TreasuryStockMember2019-12-292020-03-280000859737us-gaap:CommonStockMember2020-03-280000859737us-gaap:AdditionalPaidInCapitalMember2020-03-280000859737us-gaap:RetainedEarningsMember2020-03-280000859737us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-03-280000859737us-gaap:TreasuryStockMember2020-03-2800008597372020-03-280000859737us-gaap:CommonStockMember2020-03-292020-06-270000859737us-gaap:AdditionalPaidInCapitalMember2020-03-292020-06-2700008597372020-03-292020-06-270000859737us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-03-292020-06-270000859737us-gaap:CommonStockMember2020-06-270000859737us-gaap:AdditionalPaidInCapitalMember2020-06-270000859737us-gaap:RetainedEarningsMember2020-06-270000859737us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-06-270000859737us-gaap:TreasuryStockMember2020-06-2700008597372020-06-270000859737us-gaap:CommonStockMember2020-06-282020-09-260000859737us-gaap:AdditionalPaidInCapitalMember2020-06-282020-09-2600008597372020-06-282020-09-260000859737us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-06-282020-09-260000859737us-gaap:TreasuryStockMember2020-06-282020-09-260000859737us-gaap:CommonStockMember2020-09-260000859737us-gaap:AdditionalPaidInCapitalMember2020-09-260000859737us-gaap:RetainedEarningsMember2020-09-260000859737us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-09-260000859737us-gaap:TreasuryStockMember2020-09-260000859737us-gaap:CommonStockMember2020-09-272020-12-260000859737us-gaap:AdditionalPaidInCapitalMember2020-09-272020-12-2600008597372020-09-272020-12-260000859737us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-09-272020-12-260000859737us-gaap:TreasuryStockMember2020-09-272020-12-260000859737us-gaap:CommonStockMember2020-12-260000859737us-gaap:AdditionalPaidInCapitalMember2020-12-260000859737us-gaap:RetainedEarningsMember2020-12-260000859737us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-260000859737us-gaap:TreasuryStockMember2020-12-2600008597372020-12-260000859737us-gaap:CommonStockMember2020-12-272021-03-270000859737us-gaap:AdditionalPaidInCapitalMember2020-12-272021-03-270000859737us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-272021-03-270000859737us-gaap:TreasuryStockMember2020-12-272021-03-270000859737us-gaap:CommonStockMember2021-03-270000859737us-gaap:AdditionalPaidInCapitalMember2021-03-270000859737us-gaap:RetainedEarningsMember2021-03-270000859737us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-03-270000859737us-gaap:TreasuryStockMember2021-03-270000859737us-gaap:SubsequentEventMemberholx:MobidiagMember2021-04-082021-04-080000859737country:USholx:DiagnosticsMemberholx:CytologyPerinatalMember2020-12-272021-03-270000859737holx:InternationalMemberholx:DiagnosticsMemberholx:CytologyPerinatalMember2020-12-272021-03-270000859737holx:DiagnosticsMemberholx:CytologyPerinatalMember2020-12-272021-03-270000859737country:USholx:DiagnosticsMemberholx:CytologyPerinatalMember2019-12-292020-03-280000859737holx:InternationalMemberholx:DiagnosticsMemberholx:CytologyPerinatalMember2019-12-292020-03-280000859737holx:DiagnosticsMemberholx:CytologyPerinatalMember2019-12-292020-03-280000859737country:USholx:DiagnosticsMemberholx:MolecularDiagnosticsMember2020-12-272021-03-270000859737holx:InternationalMemberholx:DiagnosticsMemberholx:MolecularDiagnosticsMember2020-12-272021-03-270000859737holx:DiagnosticsMemberholx:MolecularDiagnosticsMember2020-12-272021-03-270000859737country:USholx:DiagnosticsMemberholx:MolecularDiagnosticsMember2019-12-292020-03-280000859737holx:InternationalMemberholx:DiagnosticsMemberholx:MolecularDiagnosticsMember2019-12-292020-03-280000859737holx:DiagnosticsMemberholx:MolecularDiagnosticsMember2019-12-292020-03-280000859737country:USholx:DiagnosticsMemberholx:BloodScreeningMember2020-12-272021-03-270000859737holx:InternationalMemberholx:DiagnosticsMemberholx:BloodScreeningMember2020-12-272021-03-270000859737holx:DiagnosticsMemberholx:BloodScreeningMember2020-12-272021-03-270000859737country:USholx:DiagnosticsMemberholx:BloodScreeningMember2019-12-292020-03-280000859737holx:InternationalMemberholx:DiagnosticsMemberholx:BloodScreeningMember2019-12-292020-03-280000859737holx:DiagnosticsMemberholx:BloodScreeningMember2019-12-292020-03-280000859737country:USholx:DiagnosticsMember2020-12-272021-03-270000859737holx:InternationalMemberholx:DiagnosticsMember2020-12-272021-03-270000859737holx:DiagnosticsMember2020-12-272021-03-270000859737country:USholx:DiagnosticsMember2019-12-292020-03-280000859737holx:InternationalMemberholx:DiagnosticsMember2019-12-292020-03-280000859737holx:DiagnosticsMember2019-12-292020-03-280000859737country:USholx:BreastHealthMemberholx:BreastImagingMember2020-12-272021-03-270000859737holx:BreastHealthMemberholx:InternationalMemberholx:BreastImagingMember2020-12-272021-03-270000859737holx:BreastHealthMemberholx:BreastImagingMember2020-12-272021-03-270000859737country:USholx:BreastHealthMemberholx:BreastImagingMember2019-12-292020-03-280000859737holx:BreastHealthMemberholx:InternationalMemberholx:BreastImagingMember2019-12-292020-03-280000859737holx:BreastHealthMemberholx:BreastImagingMember2019-12-292020-03-280000859737country:USholx:BreastHealthMemberholx:InterventionalBreastSolutionsMember2020-12-272021-03-270000859737holx:BreastHealthMemberholx:InternationalMemberholx:InterventionalBreastSolutionsMember2020-12-272021-03-270000859737holx:BreastHealthMemberholx:InterventionalBreastSolutionsMember2020-12-272021-03-270000859737country:USholx:BreastHealthMemberholx:InterventionalBreastSolutionsMember2019-12-292020-03-280000859737holx:BreastHealthMemberholx:InternationalMemberholx:InterventionalBreastSolutionsMember2019-12-292020-03-280000859737holx:BreastHealthMemberholx:InterventionalBreastSolutionsMember2019-12-292020-03-280000859737country:USholx:BreastHealthMember2020-12-272021-03-270000859737holx:BreastHealthMemberholx:InternationalMember2020-12-272021-03-270000859737holx:BreastHealthMember2020-12-272021-03-270000859737country:USholx:BreastHealthMember2019-12-292020-03-280000859737holx:BreastHealthMemberholx:InternationalMember2019-12-292020-03-280000859737holx:BreastHealthMember2019-12-292020-03-280000859737country:USholx:GynSurgicalMember2020-12-272021-03-270000859737holx:InternationalMemberholx:GynSurgicalMember2020-12-272021-03-270000859737holx:GynSurgicalMember2020-12-272021-03-270000859737country:USholx:GynSurgicalMember2019-12-292020-03-280000859737holx:InternationalMemberholx:GynSurgicalMember2019-12-292020-03-280000859737holx:GynSurgicalMember2019-12-292020-03-280000859737holx:SkeletalHealthMembercountry:US2020-12-272021-03-270000859737holx:SkeletalHealthMemberholx:InternationalMember2020-12-272021-03-270000859737holx:SkeletalHealthMember2020-12-272021-03-270000859737holx:SkeletalHealthMembercountry:US2019-12-292020-03-280000859737holx:SkeletalHealthMemberholx:InternationalMember2019-12-292020-03-280000859737holx:SkeletalHealthMember2019-12-292020-03-280000859737country:US2020-12-272021-03-270000859737holx:InternationalMember2020-12-272021-03-270000859737country:US2019-12-292020-03-280000859737holx:InternationalMember2019-12-292020-03-280000859737country:USholx:DiagnosticsMemberholx:CytologyPerinatalMember2020-09-272021-03-270000859737holx:InternationalMemberholx:DiagnosticsMemberholx:CytologyPerinatalMember2020-09-272021-03-270000859737holx:DiagnosticsMemberholx:CytologyPerinatalMember2020-09-272021-03-270000859737country:USholx:DiagnosticsMemberholx:CytologyPerinatalMember2019-09-292020-03-280000859737holx:InternationalMemberholx:DiagnosticsMemberholx:CytologyPerinatalMember2019-09-292020-03-280000859737holx:DiagnosticsMemberholx:CytologyPerinatalMember2019-09-292020-03-280000859737country:USholx:DiagnosticsMemberholx:MolecularDiagnosticsMember2020-09-272021-03-270000859737holx:InternationalMemberholx:DiagnosticsMemberholx:MolecularDiagnosticsMember2020-09-272021-03-270000859737holx:DiagnosticsMemberholx:MolecularDiagnosticsMember2020-09-272021-03-270000859737country:USholx:DiagnosticsMemberholx:MolecularDiagnosticsMember2019-09-292020-03-280000859737holx:InternationalMemberholx:DiagnosticsMemberholx:MolecularDiagnosticsMember2019-09-292020-03-280000859737holx:DiagnosticsMemberholx:MolecularDiagnosticsMember2019-09-292020-03-280000859737country:USholx:DiagnosticsMemberholx:BloodScreeningMember2020-09-272021-03-270000859737holx:InternationalMemberholx:DiagnosticsMemberholx:BloodScreeningMember2020-09-272021-03-270000859737holx:DiagnosticsMemberholx:BloodScreeningMember2020-09-272021-03-270000859737country:USholx:DiagnosticsMemberholx:BloodScreeningMember2019-09-292020-03-280000859737holx:InternationalMemberholx:DiagnosticsMemberholx:BloodScreeningMember2019-09-292020-03-280000859737holx:DiagnosticsMemberholx:BloodScreeningMember2019-09-292020-03-280000859737country:USholx:DiagnosticsMember2020-09-272021-03-270000859737holx:InternationalMemberholx:DiagnosticsMember2020-09-272021-03-270000859737holx:DiagnosticsMember2020-09-272021-03-270000859737country:USholx:DiagnosticsMember2019-09-292020-03-280000859737holx:InternationalMemberholx:DiagnosticsMember2019-09-292020-03-280000859737holx:DiagnosticsMember2019-09-292020-03-280000859737country:USholx:BreastHealthMemberholx:BreastImagingMember2020-09-272021-03-270000859737holx:BreastHealthMemberholx:InternationalMemberholx:BreastImagingMember2020-09-272021-03-270000859737holx:BreastHealthMemberholx:BreastImagingMember2020-09-272021-03-270000859737country:USholx:BreastHealthMemberholx:BreastImagingMember2019-09-292020-03-280000859737holx:BreastHealthMemberholx:InternationalMemberholx:BreastImagingMember2019-09-292020-03-280000859737holx:BreastHealthMemberholx:BreastImagingMember2019-09-292020-03-280000859737country:USholx:BreastHealthMemberholx:InterventionalBreastSolutionsMember2020-09-272021-03-270000859737holx:BreastHealthMemberholx:InternationalMemberholx:InterventionalBreastSolutionsMember2020-09-272021-03-270000859737holx:BreastHealthMemberholx:InterventionalBreastSolutionsMember2020-09-272021-03-270000859737country:USholx:BreastHealthMemberholx:InterventionalBreastSolutionsMember2019-09-292020-03-280000859737holx:BreastHealthMemberholx:InternationalMemberholx:InterventionalBreastSolutionsMember2019-09-292020-03-280000859737holx:BreastHealthMemberholx:InterventionalBreastSolutionsMember2019-09-292020-03-280000859737country:USholx:BreastHealthMember2020-09-272021-03-270000859737holx:BreastHealthMemberholx:InternationalMember2020-09-272021-03-270000859737holx:BreastHealthMember2020-09-272021-03-270000859737country:USholx:BreastHealthMember2019-09-292020-03-280000859737holx:BreastHealthMemberholx:InternationalMember2019-09-292020-03-280000859737holx:BreastHealthMember2019-09-292020-03-280000859737country:USholx:GynSurgicalMember2020-09-272021-03-270000859737holx:InternationalMemberholx:GynSurgicalMember2020-09-272021-03-270000859737holx:GynSurgicalMember2020-09-272021-03-270000859737country:USholx:GynSurgicalMember2019-09-292020-03-280000859737holx:InternationalMemberholx:GynSurgicalMember2019-09-292020-03-280000859737holx:GynSurgicalMember2019-09-292020-03-280000859737holx:MedicalAestheticsMembercountry:US2020-09-272021-03-270000859737holx:MedicalAestheticsMemberholx:InternationalMember2020-09-272021-03-270000859737holx:MedicalAestheticsMember2020-09-272021-03-270000859737holx:MedicalAestheticsMembercountry:US2019-09-292020-03-280000859737holx:MedicalAestheticsMemberholx:InternationalMember2019-09-292020-03-280000859737holx:MedicalAestheticsMember2019-09-292020-03-280000859737holx:SkeletalHealthMembercountry:US2020-09-272021-03-270000859737holx:SkeletalHealthMemberholx:InternationalMember2020-09-272021-03-270000859737holx:SkeletalHealthMember2020-09-272021-03-270000859737holx:SkeletalHealthMembercountry:US2019-09-292020-03-280000859737holx:SkeletalHealthMemberholx:InternationalMember2019-09-292020-03-280000859737holx:SkeletalHealthMember2019-09-292020-03-280000859737country:US2020-09-272021-03-270000859737holx:InternationalMember2020-09-272021-03-270000859737country:US2019-09-292020-03-280000859737holx:InternationalMember2019-09-292020-03-280000859737srt:EuropeMember2020-12-272021-03-270000859737srt:EuropeMember2019-12-292020-03-280000859737srt:EuropeMember2020-09-272021-03-270000859737srt:EuropeMember2019-09-292020-03-280000859737srt:AsiaPacificMember2020-12-272021-03-270000859737srt:AsiaPacificMember2019-12-292020-03-280000859737srt:AsiaPacificMember2020-09-272021-03-270000859737srt:AsiaPacificMember2019-09-292020-03-280000859737holx:RestofWorldMember2020-12-272021-03-270000859737holx:RestofWorldMember2019-12-292020-03-280000859737holx:RestofWorldMember2020-09-272021-03-270000859737holx:RestofWorldMember2019-09-292020-03-280000859737holx:ConsumablesMember2020-12-272021-03-270000859737holx:ConsumablesMember2019-12-292020-03-280000859737holx:ConsumablesMember2020-09-272021-03-270000859737holx:ConsumablesMember2019-09-292020-03-280000859737holx:CapitalEquipmentComponentsandSoftwareMember2020-12-272021-03-270000859737holx:CapitalEquipmentComponentsandSoftwareMember2019-12-292020-03-280000859737holx:CapitalEquipmentComponentsandSoftwareMember2020-09-272021-03-270000859737holx:CapitalEquipmentComponentsandSoftwareMember2019-09-292020-03-280000859737us-gaap:ServiceMember2020-12-272021-03-270000859737us-gaap:ServiceMember2019-12-292020-03-280000859737us-gaap:ServiceMember2020-09-272021-03-270000859737us-gaap:ServiceMember2019-09-292020-03-280000859737holx:OtherTypeofRevenueMember2020-12-272021-03-270000859737holx:OtherTypeofRevenueMember2019-12-292020-03-280000859737holx:OtherTypeofRevenueMember2020-09-272021-03-270000859737holx:OtherTypeofRevenueMember2019-09-292020-03-28xbrli:pure00008597372020-03-292021-03-2700008597372021-03-292021-03-2700008597372022-03-292021-03-2700008597372023-03-292021-03-2700008597372024-03-292021-03-270000859737us-gaap:ForeignExchangeOptionMember2021-03-270000859737us-gaap:ForeignExchangeOptionMemberus-gaap:FairValueInputsLevel1Member2021-03-270000859737us-gaap:ForeignExchangeOptionMemberus-gaap:FairValueInputsLevel2Member2021-03-270000859737us-gaap:ForeignExchangeOptionMemberus-gaap:FairValueInputsLevel3Member2021-03-270000859737us-gaap:FairValueInputsLevel1Member2021-03-270000859737us-gaap:FairValueInputsLevel2Member2021-03-270000859737us-gaap:FairValueInputsLevel3Member2021-03-270000859737holx:ContingentConsiderationMember2021-03-270000859737us-gaap:FairValueInputsLevel1Memberholx:ContingentConsiderationMember2021-03-270000859737us-gaap:FairValueInputsLevel2Memberholx:ContingentConsiderationMember2021-03-270000859737holx:ContingentConsiderationMemberus-gaap:FairValueInputsLevel3Member2021-03-270000859737us-gaap:InterestRateSwapMember2021-03-270000859737us-gaap:InterestRateSwapMemberus-gaap:FairValueInputsLevel1Member2021-03-270000859737us-gaap:InterestRateSwapMemberus-gaap:FairValueInputsLevel2Member2021-03-270000859737us-gaap:InterestRateSwapMemberus-gaap:FairValueInputsLevel3Member2021-03-270000859737us-gaap:ForeignExchangeContractMemberus-gaap:LiabilityMember2021-03-270000859737us-gaap:ForeignExchangeContractMemberus-gaap:FairValueInputsLevel1Memberus-gaap:LiabilityMember2021-03-270000859737us-gaap:ForeignExchangeContractMemberus-gaap:FairValueInputsLevel2Memberus-gaap:LiabilityMember2021-03-270000859737us-gaap:ForeignExchangeContractMemberus-gaap:LiabilityMemberus-gaap:FairValueInputsLevel3Member2021-03-270000859737holx:MedicalAestheticsMember2020-06-282020-09-260000859737holx:CreditAgreementMember2021-03-270000859737holx:A2025SeniorNotesMember2021-03-270000859737holx:A2028SeniorNotesMember2021-03-270000859737holx:BiotheranosticsMember2021-02-222021-02-220000859737holx:BiotheranosticsMember2021-02-220000859737holx:DiagenodeMember2021-03-012021-03-010000859737holx:DiagenodeMember2021-03-010000859737holx:DiagenodeMemberholx:DevelopedTechnologyMember2021-03-012021-03-010000859737holx:DiagenodeMemberus-gaap:CustomerRelationshipsMember2021-03-012021-03-010000859737holx:SomatexMedicalTechnologiesMember2021-01-042021-01-040000859737holx:SomatexMedicalTechnologiesMember2021-01-040000859737holx:NXCImagingMember2020-09-282020-09-280000859737holx:NXCImagingMemberus-gaap:CustomerRelationshipsMember2020-09-282020-09-280000859737holx:AcessaHealthMember2020-08-232020-08-230000859737holx:AcessaHealthMemberholx:ContingentHoldbackMember2020-08-230000859737holx:AcessaHealthMember2020-08-230000859737holx:AcessaHealthMember2020-12-272021-03-270000859737holx:AcessaHealthMember2020-09-272021-03-270000859737holx:DevelopedTechnologyMember2020-08-232020-08-230000859737us-gaap:TradeNamesMember2020-08-232020-08-230000859737holx:HealthBeaconsMember2020-02-032020-02-030000859737holx:HealthBeaconsMember2020-02-030000859737holx:AlphaImagingMember2019-12-302019-12-300000859737holx:AlphaImagingMember2019-12-300000859737us-gaap:CustomerRelationshipsMemberholx:AlphaImagingMember2019-12-302019-12-300000859737holx:SuperSonicImagineMember2019-08-010000859737holx:SuperSonicImagineMember2019-08-012019-08-010000859737holx:SuperSonicImagineMember2019-09-012019-09-300000859737holx:SuperSonicImagineMember2019-11-200000859737holx:SuperSonicImagineMember2019-11-212019-11-2100008597372019-11-212019-11-2100008597372019-11-012019-11-300000859737holx:SuperSonicImagineMember2020-09-272021-03-270000859737holx:SuperSonicImagineMember2021-03-270000859737holx:SuperSonicImagineMember2019-11-210000859737holx:SuperSonicImagineMemberholx:DevelopedTechnologyMember2019-11-212019-11-210000859737holx:SuperSonicImagineMemberus-gaap:CustomerRelationshipsMember2019-11-212019-11-210000859737holx:SuperSonicImagineMemberus-gaap:TradeNamesMember2019-11-212019-11-210000859737us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberholx:MedicalAestheticsMember2019-11-200000859737us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberholx:MedicalAestheticsMember2019-11-202019-11-200000859737us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberholx:MedicalAestheticsMember2020-06-282020-09-260000859737us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberholx:MedicalAestheticsMember2021-03-270000859737us-gaap:CostOfSalesMember2019-09-292019-12-280000859737us-gaap:OperatingExpenseMember2019-09-292019-12-2800008597372019-06-302019-09-280000859737holx:TermLoanMember2021-03-270000859737holx:TermLoanMember2020-09-260000859737holx:RevolverMember2021-03-270000859737holx:RevolverMember2020-09-260000859737holx:A2025SeniorNotesMember2021-03-270000859737holx:A2025SeniorNotesMember2020-09-260000859737holx:A2028SeniorNotesMember2021-03-270000859737holx:A2028SeniorNotesMember2020-09-260000859737holx:A2029SeniorNotesMember2021-03-270000859737holx:A2029SeniorNotesMember2020-09-260000859737holx:PercentageAddedtoEurodollarRateMemberholx:AmendedTermLoanMember2020-09-272021-03-270000859737holx:RevolverMember2018-12-170000859737holx:RevolverMember2020-03-310000859737holx:AccountsReceivableSecuritizationMember2019-09-292020-03-280000859737us-gaap:RevolvingCreditFacilityMember2020-09-272020-12-260000859737holx:CreditAgreementMember2020-12-272021-03-270000859737holx:CreditAgreementMember2019-12-292020-03-280000859737holx:CreditAgreementMember2020-09-272021-03-270000859737holx:CreditAgreementMember2019-09-292020-03-280000859737holx:CreditAgreementMember2020-03-280000859737holx:A2029SeniorNotesMemberus-gaap:SeniorNotesMember2020-09-280000859737holx:A2025SeniorNotesMemberus-gaap:SeniorNotesMember2021-03-270000859737holx:A2025SeniorNotesMemberus-gaap:SeniorNotesMember2020-10-150000859737holx:A2025SeniorNotesMemberus-gaap:SeniorNotesMember2020-10-152020-10-150000859737holx:A2025SeniorNotesMemberus-gaap:SeniorNotesMember2020-12-272021-03-270000859737holx:A2028SeniorNotesMemberus-gaap:SeniorNotesMember2021-03-270000859737holx:A2029SeniorNotesMemberus-gaap:SeniorNotesMember2021-03-270000859737holx:A2029SeniorNotesMemberus-gaap:SeniorNotesMember2020-09-282020-09-2800008597372020-09-282020-09-280000859737holx:A2029SeniorNotesMemberus-gaap:DebtInstrumentRedemptionPeriodOneMemberus-gaap:SeniorNotesMember2020-09-282020-09-280000859737holx:A2029SeniorNotesMemberus-gaap:DebtInstrumentRedemptionPeriodTwoMemberus-gaap:SeniorNotesMember2020-09-282020-09-280000859737holx:A2029SeniorNotesMemberus-gaap:DebtInstrumentRedemptionPeriodThreeMemberus-gaap:SeniorNotesMember2020-09-282020-09-280000859737holx:A2029SeniorNotesMemberus-gaap:DebtInstrumentRedemptionPeriodFourMemberus-gaap:SeniorNotesMember2020-09-282020-09-280000859737holx:A2029SeniorNotesMemberus-gaap:DebtInstrumentRedemptionPeriodFiveMemberus-gaap:SeniorNotesMember2020-09-282020-09-280000859737holx:A2025SeniorNotesMemberus-gaap:SeniorNotesMember2019-12-292020-03-280000859737holx:A2025SeniorNotesMemberus-gaap:SeniorNotesMember2020-09-272021-03-270000859737holx:A2025SeniorNotesMemberus-gaap:SeniorNotesMember2019-09-292020-03-280000859737holx:A2028SeniorNotesMemberus-gaap:SeniorNotesMember2020-12-272021-03-270000859737holx:A2028SeniorNotesMemberus-gaap:SeniorNotesMember2019-12-292020-03-280000859737holx:A2028SeniorNotesMemberus-gaap:SeniorNotesMember2020-09-272021-03-270000859737holx:A2028SeniorNotesMemberus-gaap:SeniorNotesMember2019-09-292020-03-280000859737holx:A2029SeniorNotesMemberus-gaap:SeniorNotesMember2020-12-272021-03-270000859737holx:A2029SeniorNotesMemberus-gaap:SeniorNotesMember2019-12-292020-03-280000859737holx:A2029SeniorNotesMemberus-gaap:SeniorNotesMember2020-09-272021-03-270000859737holx:A2029SeniorNotesMemberus-gaap:SeniorNotesMember2019-09-292020-03-2800008597372018-09-302018-12-290000859737us-gaap:InterestRateSwapMember2021-03-270000859737us-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMember2020-12-272021-03-270000859737us-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMember2019-12-292020-03-280000859737us-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMember2020-09-272021-03-270000859737us-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMember2019-09-292020-03-280000859737us-gaap:ForeignExchangeOptionMemberus-gaap:NondesignatedMember2020-12-272021-03-270000859737us-gaap:ForeignExchangeOptionMemberus-gaap:NondesignatedMember2019-12-292020-03-280000859737us-gaap:ForeignExchangeOptionMemberus-gaap:NondesignatedMember2020-09-272021-03-270000859737us-gaap:ForeignExchangeOptionMemberus-gaap:NondesignatedMember2019-09-292020-03-280000859737us-gaap:NondesignatedMember2020-12-272021-03-270000859737us-gaap:NondesignatedMember2019-12-292020-03-280000859737us-gaap:NondesignatedMember2020-09-272021-03-270000859737us-gaap:NondesignatedMember2019-09-292020-03-280000859737us-gaap:ForeignExchangeOptionMember2021-03-270000859737us-gaap:ForeignExchangeForwardMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:NondesignatedMember2021-03-270000859737us-gaap:ForeignExchangeForwardMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:NondesignatedMember2020-09-260000859737us-gaap:ForeignExchangeOptionMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:NondesignatedMember2021-03-270000859737us-gaap:ForeignExchangeOptionMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:NondesignatedMember2020-09-260000859737us-gaap:NondesignatedMember2021-03-270000859737us-gaap:NondesignatedMember2020-09-260000859737us-gaap:InterestRateSwapMemberus-gaap:NondesignatedMemberus-gaap:AccruedLiabilitiesMember2021-03-270000859737us-gaap:InterestRateSwapMemberus-gaap:NondesignatedMemberus-gaap:AccruedLiabilitiesMember2020-09-260000859737us-gaap:InterestRateSwapMemberus-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:NondesignatedMember2021-03-270000859737us-gaap:InterestRateSwapMemberus-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:NondesignatedMember2020-09-260000859737us-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMemberus-gaap:AccruedLiabilitiesMember2021-03-270000859737us-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMemberus-gaap:AccruedLiabilitiesMember2020-09-260000859737us-gaap:InterestRateSwapMember2020-12-272021-03-270000859737us-gaap:InterestRateSwapMember2019-12-292020-03-280000859737us-gaap:InterestRateSwapMember2020-09-272021-03-270000859737us-gaap:InterestRateSwapMember2019-09-292020-03-280000859737us-gaap:InterestRateCapMember2020-12-272021-03-270000859737us-gaap:InterestRateCapMember2019-12-292020-03-280000859737us-gaap:InterestRateCapMember2020-09-272021-03-270000859737us-gaap:InterestRateCapMember2019-09-292020-03-280000859737holx:MinervaMember2018-07-27holx:petition0000859737holx:MinervaMember2016-03-042016-03-040000859737holx:MedicalAestheticsMember2021-03-270000859737us-gaap:StockCompensationPlanMember2020-12-272021-03-270000859737us-gaap:StockCompensationPlanMember2019-12-292020-03-280000859737us-gaap:StockCompensationPlanMember2020-09-272021-03-270000859737us-gaap:StockCompensationPlanMember2019-09-292020-03-280000859737us-gaap:RestrictedStockUnitsRSUMember2020-12-272021-03-270000859737us-gaap:RestrictedStockUnitsRSUMember2019-12-292020-03-280000859737us-gaap:RestrictedStockUnitsRSUMember2020-09-272021-03-270000859737us-gaap:RestrictedStockUnitsRSUMember2019-09-292020-03-280000859737us-gaap:CostOfSalesMember2020-12-272021-03-270000859737us-gaap:CostOfSalesMember2019-12-292020-03-280000859737us-gaap:CostOfSalesMember2020-09-272021-03-270000859737us-gaap:CostOfSalesMember2019-09-292020-03-280000859737us-gaap:ResearchAndDevelopmentExpenseMember2020-12-272021-03-270000859737us-gaap:ResearchAndDevelopmentExpenseMember2019-12-292020-03-280000859737us-gaap:ResearchAndDevelopmentExpenseMember2020-09-272021-03-270000859737us-gaap:ResearchAndDevelopmentExpenseMember2019-09-292020-03-280000859737us-gaap:SellingAndMarketingExpenseMember2020-12-272021-03-270000859737us-gaap:SellingAndMarketingExpenseMember2019-12-292020-03-280000859737us-gaap:SellingAndMarketingExpenseMember2020-09-272021-03-270000859737us-gaap:SellingAndMarketingExpenseMember2019-09-292020-03-280000859737us-gaap:GeneralAndAdministrativeExpenseMember2020-12-272021-03-270000859737us-gaap:GeneralAndAdministrativeExpenseMember2019-12-292020-03-280000859737us-gaap:GeneralAndAdministrativeExpenseMember2020-09-272021-03-270000859737us-gaap:GeneralAndAdministrativeExpenseMember2019-09-292020-03-280000859737us-gaap:RestructuringChargesMember2020-12-272021-03-270000859737us-gaap:RestructuringChargesMember2019-12-292020-03-280000859737us-gaap:RestructuringChargesMember2020-09-272021-03-270000859737us-gaap:RestructuringChargesMember2019-09-292020-03-280000859737us-gaap:EmployeeStockOptionMember2020-09-272021-03-270000859737us-gaap:EmployeeStockOptionMember2019-09-292020-03-280000859737us-gaap:EmployeeStockOptionMember2021-03-270000859737us-gaap:RestrictedStockUnitsRSUMember2020-09-272021-03-270000859737us-gaap:RestrictedStockUnitsRSUMember2019-09-292020-03-280000859737us-gaap:PerformanceSharesMember2020-09-272021-03-270000859737us-gaap:PerformanceSharesMember2019-09-292020-03-280000859737holx:MarketBasedAwardsMember2020-09-272021-03-270000859737holx:PSUFreeCashFlowMember2020-09-272021-03-270000859737holx:PSUFreeCashFlowMember2019-09-292020-03-280000859737holx:MarketBasedAwardsMember2019-09-292020-03-280000859737holx:RSUPSUMSUMember2021-03-270000859737us-gaap:RestrictedStockUnitsRSUMember2021-03-27holx:Segment00008597372019-09-292020-06-270000859737us-gaap:IntersegmentEliminationMember2020-09-272021-03-270000859737us-gaap:IntersegmentEliminationMember2019-09-292020-03-280000859737us-gaap:IntersegmentEliminationMember2019-12-292020-03-280000859737us-gaap:IntersegmentEliminationMember2020-12-272021-03-270000859737holx:MedicalAestheticsMember2020-12-272021-03-270000859737holx:MedicalAestheticsMember2019-12-292020-03-280000859737us-gaap:CorporateMember2020-12-272021-03-270000859737us-gaap:CorporateMember2019-12-292020-03-280000859737us-gaap:CorporateMember2020-09-272021-03-270000859737us-gaap:CorporateMember2019-09-292020-03-280000859737holx:DiagnosticsMember2021-03-270000859737holx:DiagnosticsMember2020-09-260000859737holx:BreastHealthMember2021-03-270000859737holx:BreastHealthMember2020-09-260000859737holx:GynSurgicalMember2021-03-270000859737holx:GynSurgicalMember2020-09-260000859737holx:SkeletalHealthMember2021-03-270000859737holx:SkeletalHealthMember2020-09-260000859737us-gaap:CorporateMember2021-03-270000859737us-gaap:CorporateMember2020-09-260000859737holx:AllOtherCountriesMember2020-12-272021-03-270000859737holx:AllOtherCountriesMember2019-12-292020-03-280000859737holx:AllOtherCountriesMember2020-09-272021-03-270000859737holx:AllOtherCountriesMember2019-09-292020-03-280000859737holx:MedicalAestheticsMember2020-03-280000859737holx:DevelopedTechnologyMember2021-03-270000859737holx:DevelopedTechnologyMember2020-09-260000859737holx:CustomerRelationshipsContractsMember2021-03-270000859737holx:CustomerRelationshipsContractsMember2020-09-260000859737us-gaap:TradeNamesMember2021-03-270000859737us-gaap:TradeNamesMember2020-09-260000859737us-gaap:NoncompeteAgreementsMember2021-03-270000859737us-gaap:NoncompeteAgreementsMember2020-09-260000859737holx:BusinessLicensesMember2021-03-270000859737holx:BusinessLicensesMember2020-09-260000859737holx:AcquiredintangibleassetsMember2021-03-270000859737holx:AcquiredintangibleassetsMember2020-09-260000859737holx:InternalusesoftwareMember2021-03-270000859737holx:InternalusesoftwareMember2020-09-260000859737holx:CapitalizedsoftwareMember2021-03-270000859737holx:CapitalizedsoftwareMember2020-09-260000859737us-gaap:AccumulatedTranslationAdjustmentMember2020-12-260000859737us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2020-12-260000859737us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:InterestRateCapMember2020-12-260000859737us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:InterestRateSwapMember2020-12-260000859737us-gaap:AccumulatedTranslationAdjustmentMember2020-09-260000859737us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2020-09-260000859737us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:InterestRateCapMember2020-09-260000859737us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:InterestRateSwapMember2020-09-260000859737us-gaap:AccumulatedTranslationAdjustmentMember2020-12-272021-03-270000859737us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2020-12-272021-03-270000859737us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:InterestRateCapMember2020-12-272021-03-270000859737us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:InterestRateSwapMember2020-12-272021-03-270000859737us-gaap:AccumulatedTranslationAdjustmentMember2020-09-272021-03-270000859737us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2020-09-272021-03-270000859737us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:InterestRateCapMember2020-09-272021-03-270000859737us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:InterestRateSwapMember2020-09-272021-03-270000859737us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-09-272021-03-270000859737us-gaap:AccumulatedTranslationAdjustmentMember2021-03-270000859737us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-03-270000859737us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:InterestRateCapMember2021-03-270000859737us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:InterestRateSwapMember2021-03-270000859737us-gaap:AccumulatedTranslationAdjustmentMember2019-12-280000859737us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2019-12-280000859737us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:InterestRateCapMember2019-12-280000859737us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:InterestRateSwapMember2019-12-280000859737us-gaap:AccumulatedTranslationAdjustmentMember2019-09-280000859737us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2019-09-280000859737us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:InterestRateCapMember2019-09-280000859737us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:InterestRateSwapMember2019-09-280000859737us-gaap:AccumulatedTranslationAdjustmentMember2019-12-292020-03-280000859737us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2019-12-292020-03-280000859737us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:InterestRateCapMember2019-12-292020-03-280000859737us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:InterestRateSwapMember2019-12-292020-03-280000859737us-gaap:AccumulatedTranslationAdjustmentMember2019-09-292020-03-280000859737us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2019-09-292020-03-280000859737us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:InterestRateCapMember2019-09-292020-03-280000859737us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:InterestRateSwapMember2019-09-292020-03-280000859737us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-09-292020-03-280000859737us-gaap:AccumulatedTranslationAdjustmentMember2020-03-280000859737us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2020-03-280000859737us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:InterestRateCapMember2020-03-280000859737us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:InterestRateSwapMember2020-03-280000859737holx:December112019Member2019-12-110000859737holx:December112019Member2020-09-272020-12-260000859737holx:December112020Member2019-12-110000859737holx:December112020Member2020-12-272021-03-270000859737holx:December112020Member2021-03-27

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
__________________________________________________________ 
FORM 10-Q
 
 __________________________________________________________ 
(Mark One)
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 27, 2021
or 
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from                      to                     
Commission File Number: 1-36214
__________________________________________________________ 
HOLOGIC, INC.
(Exact name of registrant as specified in its charter)
 __________________________________________________________
Delaware 04-2902449
(State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.)
250 Campus Drive, 
Marlborough,
Massachusetts
01752
(Address of principal executive offices) (Zip Code)
(508) 263-2900
(Registrant’s telephone number, including area code)
 __________________________________________________________
*Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $0.01 par valueHOLXNASDAQ
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes      No  
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes      No  
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.:
Large accelerated filer   Accelerated filer 
Non-accelerated filer 
  Smaller reporting company 
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes      No  
As of April 22, 2021, 256,233,027 shares of the registrant’s Common Stock, $0.01 par value, were outstanding.


Table of Contents
HOLOGIC, INC.
INDEX
 
 Page
Item 1.
Item 2.
Item 3.
Item 4.
Item 1.
Item 1A.
Item 2.
Item 6.
EXHIBITS

2

Table of Contents
PART I – FINANCIAL INFORMATION
 
Item 1.    Financial Statements (unaudited)
HOLOGIC, INC.
CONSOLIDATED STATEMENTS OF INCOME
(Unaudited)

(In millions, except number of shares, which are reflected in thousands, and per share data)
 Three Months EndedSix Months Ended
 March 27,
2021
March 28,
2020
March 27,
2021
March 28,
2020
Revenues:
Product$1,378.8 $623.6 $2,834.2 $1,322.9 
Service and other158.8 132.5 313.2 283.7 
1,537.6 756.1 3,147.4 1,606.6 
Costs of revenues:
Product300.7 223.3 585.2 460.8 
Amortization of acquired intangible assets64.5 62.9 126.1 126.5 
Impairment of intangible assets and equipment   25.8 
Service and other86.6 74.1 170.0 163.9 
Gross profit1,085.8 395.8 2,266.1 829.6 
Operating expenses:
Research and development71.5 49.3 130.7 110.4 
Selling and marketing131.5 110.6 259.5 255.4 
General and administrative88.9 67.0 180.4 154.7 
Amortization of acquired intangible assets10.2 10.1 20.4 19.2 
Impairment of intangible assets and equipment   4.4 
Contingent consideration fair value adjustments(14.7)(0.5)(10.1)0.4 
Restructuring and divestiture charges1.6 2.9 3.0 3.9 
289.0 239.4 583.9 548.4 
Income from operations796.8 156.4 1,682.2 281.2 
Interest income0.3 1.3 0.7 3.5 
Interest expense(21.3)(31.3)(49.3)(64.1)
Debt extinguishment loss  (21.6) 
Other income (expense), net4.7 (7.5)0.9 (4.2)
Income before income taxes780.5 118.9 1,612.9 216.4 
Provision (benefit) for income taxes161.1 24.1 340.1 (264.3)
Net income$619.4 $94.8 $1,272.8 $480.7 
Net loss attributable to noncontrolling interest(0.5)(1.5)(1.5)(1.8)
Net income attributable to Hologic$619.9 $96.3 $1,274.3 $482.5 
Net income per common share attributable to Hologic:
Basic$2.40 $0.37 $4.93 $1.82 
Diluted$2.38 $0.36 $4.88 $1.81 
Weighted average number of shares outstanding:
Basic258,473 263,238 258,539 265,566 
Diluted260,749 264,506 261,267 267,114 
See accompanying notes.
3

Table of Contents
HOLOGIC, INC.
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(Unaudited)
(In millions)
 Three Months EndedSix Months Ended
 March 27,
2021
March 28,
2020
March 27,
2021
March 28,
2020
Net income$619.4 $94.8 $1,272.8 $480.7 
Changes in foreign currency translation adjustment(9.4)(5.4)8.4 2.9 
Changes in value of hedged interest rate swaps and interest rate caps, net of tax of $1.4 and $1.2 for the three and six months ended March 27, 2021 and $(8.1) and $(6.4) for the three and six months ended March 28, 2020.
Gain (loss) recognized in other comprehensive income, net4.3 (25.2)5.0 (21.2)
Loss reclassified from accumulated other comprehensive loss to the statements of income 0.4 0.5 1.7 
Other comprehensive (loss) income(5.1)(30.2)13.9 (16.6)
Comprehensive income$614.3 $64.6 $1,286.7 $464.1 
Components of comprehensive income attributable to noncontrolling interest:
Net loss attributable to noncontrolling interest0.5 1.5 1.5 1.8 
Comprehensive loss attributable to noncontrolling interest0.5 1.5 1.5 1.8 
Comprehensive income attributable to Hologic$614.8 $66.1 $1,288.2 $465.9 
See accompanying notes.


4

Table of Contents
HOLOGIC, INC.

CONSOLIDATED BALANCE SHEETS
(Unaudited)
(In millions, except number of shares, which are reflected in thousands, and par value)
 
March 27,
2021
September 26,
2020
ASSETS
Current assets:
Cash and cash equivalents$816.4 $701.0 
Accounts receivable, less reserves of $41.7 and $31.6, respectively
1,212.3 1,028.9 
Inventories456.2 395.1 
Prepaid income taxes85.4 38.8 
Prepaid expenses and other current assets92.1 58.5 
Total current assets2,662.4 2,222.3 
Property, plant and equipment, net533.6 491.5 
Intangible assets, net1,447.6 1,307.5 
Goodwill2,857.2 2,657.9 
Other assets543.2 516.6 
Total assets$8,044.0 $7,195.8 
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Current portion of long-term debt$74.9 $324.9 
Accounts payable225.1 178.8 
Accrued expenses534.9 547.6 
Deferred revenue198.5 186.1 
Finance lease obligations3.0 1.9 
Total current liabilities1,036.4 1,239.3 
Long-term debt, net of current portion2,672.1 2,713.9 
Finance lease obligations - long term23.6 17.4 
Deferred income tax liabilities229.8 201.8 
Deferred revenue13.4 12.9 
Other long-term liabilities273.7 303.2 
Stockholders’ equity:
Preferred stock, $0.01 par value – 1,623 shares authorized; 0 shares issued
  
Common stock, $0.01 par value –750,000 shares authorized; 296,887 and 295,107 shares issued, respectively
3.0 2.9 
Additional paid-in-capital5,927.1 5,904.8 
Accumulated deficit(298.9)(1,573.2)
Treasury stock, at cost – 40,682 and 37,609 shares, respectively
(1,801.0)(1,579.6)
Accumulated other comprehensive loss(35.8)(49.7)
Total Hologic's stockholders’ equity3,794.4 2,705.2 
Noncontrolling interest0.6 2.1 
Total stockholders’ equity3,795.0 2,707.3 
Total liabilities and stockholders’ equity$8,044.0 $7,195.8 
See accompanying notes.
5

Table of Contents
Hologic, Inc.
Consolidated Statements of Stockholders' Equity
(In millions, except number of shares, which are reflected in thousands)
 Common StockAdditional
Paid-in-
Capital
Accumulated
Deficit
Accumulated
Other
Comprehensive
Loss
Treasury StockTotal
Stockholders’
Equity
 Number of
Shares
Par ValueNumber of
Shares
AmountNoncontrolling Interest
Balance at September 28, 2019292,323 $2.9 $5,769.8 $(2,688.7)$(42.3)24,638 $(926.0)$ $2,115.7 
Noncontrolling interest created in acquisition— — — — — — — 8.6 8.6 
Accounting standard transition adjustment - ASC 842— — — 0.3 — — — — 0.3 
Exercise of stock options540 — 13.8 — — — — — 13.8 
Vesting of restricted stock units, net of shares withheld for employee taxes476 — (10.9)— — — — — (10.9)
Stock-based compensation— — 18.1 — — — — — 18.1 
Net income (loss)— — — 386.1 — — — (0.3)385.8 
Other comprehensive income activity— — — — 13.6 — — — 13.6 
Repurchase of common stock— — — — — 1,545 (80.9)— (80.9)
Accelerated share repurchase agreement— — (41.0)— — 3,279 (164.0)— (205.0)
Purchase of non-controlling interest— — — — — — — (1.4)(1.4)
Balance at December 28, 2019293,339 $2.9 $5,749.8 $(2,302.3)$(28.7)29,462 $(1,170.9)$6.9 $2,257.7 
Exercise of stock options503 — 13.9 — — — — — 13.9 
Vesting of restricted stock units, net of shares withheld for employee taxes86 — (1.6)— — — — — (1.6)
Common stock issued under the employee stock purchase plan214 — 8.8 — — — — — 8.8 
Stock-based compensation— — 15.7 — — — — — 15.7 
Net income (loss)— — — 96.3 — — — (1.5)94.8 
Other comprehensive income activity— — — — (30.2)— — — (30.2)
Repurchase of common stock— — — — — 5,851 (267.6)— (267.6)
Completion of Accelerated share repurchase agreement— — 41.0 — — 628 (41.0)—  
Purchase of non-controlling interest— — — — — — — (0.3)(0.3)
Balance at March 28, 2020294,142 $2.9 $5,827.6 $(2,206.0)$(58.9)35,941 $(1,479.5)$5.1 $2,091.2 
Exercise of stock options533 — 14.4 — — — — — 14.4 
6

Table of Contents
Vesting of restricted stock units, net of shares withheld for employee taxes9 — (0.2)— — — — — (0.2)
Stock-based compensation— — 19.9 — — — — — 19.9 
Net income (loss)— — — 137.9 — — — (1.5)136.4 
Other comprehensive income activity— — — — (3.0)— — — (3.0)
Purchase of non-controlling interest— — — — — — — (0.1)(0.1)
Balance at June 27, 2020294,684 $2.9 $5,861.7 $(2,068.1)$(61.9)35,941 $(1,479.5)$3.5 $2,258.6 
Exercise of stock options185 — 6.2 — — — — — 6.2 
Vesting of restricted stock units, net of shares withheld for employee taxes40 — (1.5)— — — — — (1.5)
Common stock issued under the employee stock purchase plan198 — 8.8 — — — — — 8.8 
Stock-based compensation— — 29.6 — — — — — 29.6 
Net income (loss)— — — 494.9 — — — (1.4)493.5 
Other comprehensive income activity— — — — 12.2 — — — 12.2 
Repurchase of common stock— — — — — 1,668 (100.1)— (100.1)
Balance at September 26, 2020295,107 $2.9 $5,904.8 $(1,573.2)$(49.7)37,609 $(1,579.6)$2.1 $2,707.3 
Exercise of stock options490 — 18.4 — — — — — 18.4 
Vesting of restricted stock units, net of shares withheld for employee taxes936 0.1 (46.5)— — — — — (46.4)
Stock-based compensation— — 18.6 — — — — — 18.6 
Net income (loss)— — — 654.4 — — — (1.0)653.4 
Other comprehensive income activity— — — — 19.0 — — — 19.0 
Repurchase of common stock— — — — — 1,469 (101.3)— (101.3)
Balance at December 26, 2020296,533 $3.0 $5,895.3 $(918.8)$(30.7)39,078 $(1,680.9)$1.1 $3,269.0 
Exercise of stock options146 — 5.8 — — — — — 5.8 
Vesting of restricted stock units, net of shares withheld for employee taxes17 — (0.3)— — — — — (0.3)
Common stock issued under the employee stock purchase plan191 — 9.2 — — — — — 9.2 
Stock-based compensation— — 17.1 — — — — — 17.1 
Net income (loss)— —  619.9 — — — (0.5)619.4 
Other comprehensive income activity— — — — (5.1)— — — (5.1)
7

Table of Contents
Repurchase of common stock— — — — — 1,604 (120.1)— (120.1)
Balance at March 27, 2021296,887 $3.0 $5,927.1 $(298.9)$(35.8)40,682 $(1,801.0)$0.6 $3,795.0 


8

Table of Contents
HOLOGIC, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
(In millions)
Six Months Ended
 March 27,
2021
March 28,
2020
OPERATING ACTIVITIES
Net income $1,272.8 $480.7 
Adjustments to reconcile net income to net cash provided by operating activities: